Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.

Article  PubMed  Google Scholar 

Mancia Chairperson G, Kreutz Co-Chair R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023.

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.

Article  PubMed  Google Scholar 

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease Evidence from genetic, epidemiologic, and clinical studies A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405.

Article  PubMed  Google Scholar 

Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

Article  PubMed  CAS  Google Scholar 

Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–64.

Article  PubMed  Google Scholar 

Grassi G, Del Pinto R, Agabiti Rosei C, Agnoletti D, Borghi C, Cicero AFG, et al. Reduction of high cholesterol levels by a preferably fixed-combination strategy as the first step in the treatment of hypertensive patients with hypercholesterolemia and high/very high cardiovascular risk: a consensus document by the italian society of hypertension. High Blood Press Cardiovasc Prev. 2022;29(2):105–13.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Members ATF, (CPG) ECfPG, Societies ENC. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205.

Volpe M, Tocci G. 2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. J Hypertens Suppl. 2009;27(3):S3-11.

Article  PubMed  CAS  Google Scholar 

McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018.

Article  PubMed  Google Scholar 

Collaboration S-DWGatECR 2023 SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023;44(28):2544-56.

Collaboration SwgaECr. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-54.

Collaboration S-OwgaECr. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42(25):2455-67.

Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC health promotion series. J Am Coll Cardiol. 2018;72(10):1141–56.

Article  PubMed  CAS  Google Scholar 

Group L-CW. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions. Eur J Prev Cardiol. 2024.

Jaspers NEM, Blaha MJ, Matsushita K, van der Schouw YT, Wareham NJ, Khaw KT, et al. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. Eur Heart J. 2020;41(11):1190–9.

Article  PubMed  CAS  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082–143.

PubMed  Google Scholar 

Filipiak KJ, Babkowski MC, Cameli M, Carugo S, Ferri C, Irisov DB, et al. TIMES TO ACT Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022 Dyslipidemia and arterial hypertension: the two most important and modifiable risk factors in clinical practice. Cardiol J. 2022;29(5):730–8.

Article  PubMed  PubMed Central  Google Scholar 

Volpe M, Gallo G, Modena MG, Ferri C, Desideri G, Tocci G, et al. Updated recommendations on cardiovascular prevention in 2022: An executive document of the Italian society of cardiovascular prevention. High Blood Press Cardiovasc Prev. 2022;29(2):91–102.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lin DY, Tsai CL, Chang YH, Liang CH, Chuang JY, Chen YH, et al. Real-world data on comparison of lipid-lowering effects between alirocumab and evolocumab in patients with hypercholesterolemia. Acta Cardiol Sin. 2022;38(6):778–83.

PubMed  PubMed Central  Google Scholar 

Gaba P, O’Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. Circulation. 2023;147(16):1192–203.

Article  PubMed  CAS  Google Scholar 

Ray KK, Troquay RPT, Visseren FLJ, Leiter LA, Scott Wright R, Vikarunnessa S, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109–19.

Article  PubMed  CAS  Google Scholar 

Goodman SG, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Diaz R, et al. Long-term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo-controlled observation in the ODYSSEY OUTCOMES Trial. J Am Heart Assoc. 2023;12(18): e029216.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gargiulo P, Basile C, Cesaro A, Marzano F, Buonocore D, Asile G, et al. Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT). Atherosclerosis. 2023;366:32–9.

Article  PubMed  CAS  Google Scholar 

Warden BA, Cardiology BA, Purnell JQ, Duell PB, Fazio S. Real-world utilization of bempedoic acid in an academic preventive cardiology practice. J Clin Lipidol. 2022;16(1):94–103.

Article  PubMed  Google Scholar 

Costa S, Biscaia JL, Horta MR, Romano S, Guerreiro J, Heudtlass P, et al. Real-World Effectiveness in Hypertension and Hyperlipidemia Collaborative Management between Pharmacies and Primary Care in Portugal: a Multicenter Pragmatic Controlled Trial (USFarmácia. Int J Environ Res Public Health. 2023;20(15):6496.

Article  PubMed  PubMed Central  Google Scholar 

Del Pinto R, Giua C, Keber E, Grippa E, Tilotta M, Ferri C. Impact of 2021 ESC guidelines for cardiovascular disease prevention on hypertensive patients risk: Secondary analysis of save your heart study. High Blood Press Cardiovasc Prev. 2023;30(2):167–73.

Article  PubMed  PubMed Central  Google Scholar 

Eichler HG, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, et al. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021;109(5):1212–8.

Article  PubMed  Google Scholar 

Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022;22(1):287.

Article  PubMed  PubMed Central  Google Scholar 

Kympouropoulos S. Real World Evidence: methodological issues and opportunities from the European Health Data Space. BMC Med Res Methodol. 2023;23(1):185.

Article  PubMed  PubMed Central  Google Scholar 

Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454–63.

Article  PubMed  Google Scholar 

Cicero AFG, Landolfo M, Ventura F, Borghi C. Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opin Pharmacother. 2019;20(10):1277–88.

Article  PubMed  Google Scholar 

Averna M, Banach M, Bruckert E, Drexel H, Farnier M, Gaita D, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021;325:99–109.

Article  PubMed  CAS  Google Scholar 

Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018;11(11):CD12502.

Google Scholar 

Ferri N, Ruscica M, Fazio S, Corsini A. Low-density lipoprotein cholesterol-lowering drugs: A narrative review. J Clin Med. 2024;13(4):943.